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Background: Plasminogen activator inhibitor 1 (PAI-1) overexpression is an important prognostic and predictive
biomarker in human breast cancer. SERBP1, a protein that is supposed to regulate the stability of PAI-1 mRNA, may
play a role in gynaecological cancers as well, since upregulation of SERBP1 was described in ovarian cancer
recently. This is the first study to present a systematic characterisation of SERBP1 expression in human breast cancer
and normal breast tissue at both the mRNA and the protein level.
Methods: Using semiquantitative realtime PCR we analysed SERBP1 expression in different normal human tissues
(n = 25), and in matched pairs of normal (n = 7) and cancerous breast tissues (n = 7). SERBP1 protein expression was
analysed in two independent cohorts on tissue microarrays (TMAs), an initial evaluation set, consisting of 193 breast
carcinomas and 48 normal breast tissues, and a second large validation set, consisting of 605 breast carcinomas. In
addition, a collection of benign (n = 2) and malignant (n = 6) mammary cell lines as well as breast carcinoma lysates
(n = 16) were investigated for SERBP1 expression by Western blot analysis. Furthermore, applying non-radioisotopic
in situ hybridisation a subset of normal (n = 10) and cancerous (n = 10) breast tissue specimens from the initial TMA
were analysed for SERBP1 mRNA expression.
Results: SERBP1 is not differentially expressed in breast carcinoma compared to normal breast tissue, both at the
RNA and protein level. However, recurrence-free survival analysis showed a significant correlation (P = 0.008)
between abundant SERBP1 expression in breast carcinoma and favourable prognosis. Interestingly, overall survival
analysis also displayed a tendency (P = 0.09) towards favourable prognosis when SERBP1 was overexpressed in
breast cancer.
Conclusions: The RNA-binding protein SERBP1 is abundantly expressed in human breast cancer and may represent
a novel breast tumour marker with prognostic significance. Its potential involvement in the plasminogen activator
protease cascade warrants further investigation.
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SERBP1 (PAI-RBP1) is a PAI-1 (plasminogen activator
inhibitor 1) mRNA binding protein encoded by the
SERBP1 gene localised on chromosome 1p31 [1].
SERBP1 is supposed to regulate the stability of PAI-1
mRNA by binding to its cyclic nucleotide-responsive se-
quence (CRS) [2]. Interestingly, it has been found that
binding of SERBP1 protein to PAI-1 mRNA may either
stabilise or destabilise the PAI-1 transcript depending on
the intracellular localisation of SERBP1 [2]. Cyclic
nucleotides are thought to control this process by
recruiting SERBP1 to the nucleus if the protein acts to
stabilise or to the cytoplasm if it acts to destabilise PAI-1
mRNA [2]. Yet the exact molecular mechanisms of this
dual behaviour have not been elucidated [3]. SERBP1
was also assigned a role in chromatin architecture as it
was found to interact with the C-terminal region of the
human chromatin remodelling factor CHD-3 (chromo-
helicase-DNA-binding domain protein-3) [4]. CHD pro-
teins are members of the chromodomain family, a class
of proteins which are involved in chromatin remodelling
and transcriptional regulation [4]. Clearly, chromatin re-
modelling is a key process in the regulation of gene ex-
pression since it affects the DNA’s tertiary and higher
order structures including nucleosome packing, the for-
mation of DNA loops or its supercoiling [5]. Further-
more, SERBP1 is known to mediate non-nuclear
progesterone effects by binding to PGRMC1 (progester-
one receptor membrane component-1) which is involved
in mediating antiapoptotic actions of progesterone [6].
As above mentioned, SERBP1 is a binding protein of
PAI-1 mRNA [1]. Both PAI-1 (plasminogen activator in-
hibitor 1) and uPA (urokinase-type plasminogen activa-
tor) are part of the plasminogen activator (PA) system
playing a central role in physiological processes includ-
ing fibrinolysis, angiogenesis and wound healing as well
as in tumour cell invasion and metastasis [7,8]. Plas-
minogen activation results in the formation of plasmin,
a serine protease, which activates the proenzyme uPA to
the proteolytic active uPA and is also the activator of
several matrix metalloproteinases leading to degradation
of the extracellular matrix and basement membrane
[7,8]. Overexpression of uPA and PAI-1 has been found
in malignant solid tumours in a variety of human can-
cers, including ovarian and breast cancer [7-9]. High
protein levels of uPA and PAI-1 are associated with poor
prognosis in lymph node-negative breast cancer patients
and are established predictive factors in clinical practice
[10,11]. In ovarian cancer, overexpression of uPA and
PAI-1 was correlated with poor clinical outcome as well
[12,13]. Recently, overexpression of the PAI-1 mRNA
binding protein (SERBP1) was also detected in ovarian
cancer where it significantly correlated with advanced
tumour stage [1]. In human breast cancer expression ofSERBP1 has not been examined so far. To our best
knowledge, this is the first study that systematically ana-
lysed the expression of SERBP1 in human breast carcin-
omas and normal breast tissues both at the mRNA and
the protein level. We analysed the results especially in
correlation to clinicopathological data like hormone re-
ceptor status, HER2 status and patient survival in order
to validate SERBP1 as a new prognostic marker and po-
tential drug target in the treatment of human breast
cancer.
Methods
SERBP1 protein expression in breast cancer patients was
assessed using two independent breast cancer cohorts
on TMAs. The first tumour cohort has been previously
described [14,15] and consisted of 193 breast cancer spe-
cimens and 48 normal breast tissue specimens. The
TMA contained one tissue core from non-selected,
formalin-fixed and paraffin-embedded primary breast
cancer specimens diagnosed between 1994 and 2002 at
the Institute of Pathology, University of Regensburg,
Germany. Patients’ age ranged from 25 to 82 years with
a median age of 56 years. An experienced surgical path-
ologist (A.H.) evaluated H&E-stained slides of all speci-
mens prior to construction of the TMA in order to
identify representative tumour areas. Histologically, all
tumours were graded according to Elston and Ellis [16].
Clinical follow-up data, provided by the Central Tumour
Registry, Regensburg, Germany were available for all 193
breast cancer patients with a median follow-up period of
78 months (range 0-148 months).
The second TMA for validation consisted of 967
breast specimens of which 605 breast carcinomas were
analysable. The second TMA was constructed from a
cohort of breast cancer patients who were participants
of a case control trial for the assessment of breast cancer
susceptibility markers and prognostic factors, the Bavar-
ian Breast Cancer Cases and Controls Study (BBCC),
which has been described previously, including methods
for the data collection [17,18]. Briefly, database closure
for this analysis was December 31, 2008 with a median
follow up of 5.3 years. Of 967 BBCC patients a paraffin
embedded tissue was available. A 0.6 mm punch was
retrieved from the breast cancer tumour after a patholo-
gist (A.D.) evaluated H&E-stained slides of all speci-
mens. Data concerning the hormone receptor status
were obtained from original pathological reports of these
specimens; the other data were collected from the
patients’ medical records and an epidemiological ques-
tionnaire which was completed in a personal interview.
All patients included in this study gave informed con-
sent for further analysis of their tissue for research pur-
poses and publication of the data. The Instructional
Review Board of the participating centre approved the
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Friedrich-Alexander University of Erlangen, reference
number: 2700; Ethics Committee of the Medical Faculty
of the University of Aachen (reference number: 206/09)
and Regensburg).
Benign human tissue mRNAs
For RT-PCR analysis commercially available mRNAs
(Clontech, Germany) derived from different benign
human organs (n = 25) were used. Tissue included in
this selection were skeletal muscle, heart, spinal cord,
brain, thymus, kidney, colon, bone marrow, placenta, ad-
renal gland, prostate, stomach, trachea, small intestine,
uterus, thyroid, lymph node, pituitary gland, mammary
gland, spleen, pancreas, cervix, salivary gland, testis and
liver.
Cryoconserved human breast cancer samples
For Western blot analysis we used lysates of cryocon-
served human breast cancer tissues with low (n = 8) and
high (n = 8) levels of PAI-1 protein. The PAI-
concentrations were measured by application of a
commercially available ELISA-test (FEMTELLEW). As
established in clinical routine, a PAI-1 level <14 ng/mg
total protein was defined as low and >14 ng/mg total pro-
tein as high [10,11]. Additionally we analysed cryoconserved
matched pairs of normal (n = 7) and cancerous (n = 7)
breast tissue samples for mRNA expression analysis.
Cell lines
The human mammary epithelial cell lines MCF12A and
MCF10A as well as the breast cancer cell lines ZR75-1,
BT20, HS578T, SKBR3, MDA-MB468 and MDA-MB231
were obtained from the ATCC (Rockville, MD, USA)
and cultured as previously described [19].
RNA extraction and reverse transcription
Total RNA was isolated by use of TRIzol reagent (Invi-
trogen, Carlsbad, CA, USA) according to the manufac-
turers’ recommendations. Of the obtained RNA, 1 μg
was reverse transcribed using the Reverse Transcription
System (Promega, Madison, WI, USA). In order to im-
prove transcription rate we mixed oligo-dT and pdN6
primers 1:1.
Semiquantitative realtime PCR
Semiquantitative PCR was performed using the LightCy-
cler system together with the LightCycler DNA Master
SYBR Green I Kit (Roche Diagnostics, Mannheim, Ger-
many) [19]. To ensure experiment accuracy, all reactions
were performed in triplicate. Primer sequences were:
SERBP1 sense 50- CCA CCT CGT GAA CGA AGA TT
-30 and antisense 50- ACC ACC ACG ACC TCG AAT
AG -30; GAPDH sense 50- GAA GGT GAA GGT CGGAGT CA -30 and antisense 50- AAT GAA GGG CTC
ATT GAT GG -30. Annealing temperatures for both
genes were set to 60°C. Reaction specificity was con-
trolled by post-amplification melting curve analyses as
well as by gel electrophoresis of the obtained products.
Non-radioisotopic in situ hybridisation
Non-radioisotopic RNA in situ hybridisation [20,21] was
used to analyse the mRNA expression of SERBP1. In
short, cRNA sense and antisense probes were tran-
scribed from linearised SERBP1 cDNA clone AA164643
using an in vitro transcription kit (Roche Diagnostics,
Mannheim, Germany) according to the instructions of
the manufacturer. The size of the in vitro transcribed
RNA was confirmed by agarose gel electrophoresis. Par-
affin embedded tissue sections were deparaffinised, rehy-
drated and fixed prior to hybridisation. Hybridisation of
sections was performed in hybridisation buffer contain-
ing 2.5 ng/μl Digoxigenin-labeled RNA probes for 12 h
at 65°C. After stringent washes to remove excess probe,
the slides were incubated with the anti-DIG-AP anti-
body (Roche Diagnostics, Mannheim, Germany) for 12 h
at 4°C in order to visualise the hybridised transcripts.
The slides were then rinsed for 2–4 days in washing buf-
fer. For detection of hybridisation signals, slides were
incubated in 1 ml BM-Purple (Roche Diagnostics,
Mannheim, Germany) containing 2 mM Levamisol and
0.1% Tween-20. Sections were counterstained with
Texas Fast Red (Sigma, Munich, Germany).
Immunohistochemistry
Immunohistochemical (IHC) studies for the expression
of HER2 utilised an avidin-biotin peroxidase method
with a 3,30-diaminobenzidine (DAB) chromatogen. After
antigen retrieval (microwave oven for 30 min at 200 W)
IHC was carried out in a NEXES immunostainer (Ven-
tana, Tucson, AZ, USA) following the manufacturer’s
instructions. The following primary antibodies were
used: anti-HER2 (DAKO, Hamburg, Germany; 1:400),
anti-ER and anti-PR (Novocastra, Newcastle Upon Tyne,
UK; 1:20). For target proteins the ChemMate detection
kit (DAKO) was used. A surgical pathologist (A.H.) per-
formed a blinded evaluation of the TMA slides without
knowledge of clinical data. Causes of non-interpretable
results included lack of tumour tissue and presence of
necrosis or crush artefacts. HER2 expression was scored
according to the DAKO HercepTest. For the evaluation
of ER and PR presence, a semiquantitative immunoreac-
tivity score (IRS), as described by Remmele and Stegner
[22], was used considering staining intensity and per-
centage of positive cell nuclei. The staining intensity was
described by scores between 0 and 3 (0 = no reaction,
1 = low, 2 =moderate, 3 = strong). Accordingly, the
number of positive cell nuclei was counted and scored
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positive cell nuclei, 2 = 10-50% positive cell nuclei,
3 = 51-80% positive cell nuclei, 4 = > 80% positive cell
nuclei). The product of staining intensity and percentage
of positive cell nuclei resulted in a score (IRS) between 0
and 12. Each sample was categorised by this rating score.
Immunohistochemical evaluation of nuclear and cyto-
plasmic staining for SERBP1 was done equivalently [22].
Generation of a polyclonal SERBP1 antibody
As we started our investigations commercial polyclonal
SERBP1 antibodies which were applicable for immuno-
histochemistry on paraffin embedded tissues were not
available. Therefore we commissioned Eurogentec Inc.
(Liège, Belgium) to produce a polyclonal SERBP1 anti-
body. Eurogentec gained the SERBP1 antibody by im-
munisation of rabbits with the corresponding peptide
(peptide sequence: CKKEGIRRVGRR). Specificity was
proven by a peptide competition experiment using
Western blot analysis (Additional file 1: Figure S1).
SERBP1 Immunohistochemistry
The tissue microarrays – both, the evaluation set and
the validation set - were subjected to immunostaining
using the Advance Kit (DAKO K4068) following the
manufacturer’s instructions. Paraffin-embedded breast
carcinomas served as positive controls. After deparaffini-
sation and rehydration the tissue samples were boiled in
a microwave oven for 30 min at 200 W in 10 mM so-
dium citrate buffer (pH 7.2). Endogenous peroxidase
was blocked by peroxidase blocking solution (DAKO
S2023) for 5 min. The polyclonal primary antibody
SERBP1 (Eurogentec, EP060994, rabbit, Liège, Belgium)
was applied (1:40 dilution) for 30 min at room
temperature. In negative controls the primary antibody
was omitted. For signal detection 3,30-diaminobenzidine
(DAB) was used. Slides were counterstained with
hematoxylin and after dehydration mounted in Vitro-
Clud (Langenbrinck, Emmendingen, Germany). Two
experienced pathologists (N.B.S., A.H.) scored the
immunohistochemical staining intensity according to the
scoring system suggested by Remmele and Stegner [22].
SERBP1 Western blot analysis
Cell lines were lysed in NP40 buffer (1% Nonidet P-40,
150 mM NaCl, 25 mM Tris-HCl pH 7.6, 1 mM DTT,
1 mM EDTA, 1 mM Sodium Orthovanadat, proteinase
inhibitor (Roche, Lewes, UK)), sonicated for 30 sec and
finally centrifuged for 30 min at 13.000 rpm. 20 μl of the
supernatant (approximately 15-20 μg protein) was then
mixed with 4x NuPage buffer (Invitrogen) and run on a
4-12% Bis-Tris Gel (Invitrogen).
Lysis of frozen tissue samples was processed according to
the recommendations of the Femtelle Kit (FEMTELLEW).Approximately 100-150 mg cryoconserved tissue was
homogenised with mortar and pestle. Next lysis was per-
formed through addition of 2 ml lysis buffer (1,8 ml TBS
(pH 8,5) + 0,2 ml 10% Triton-X-100) and centrifugation for
1 h at 100.000 g. 25 μl of the supernatant (approximately
15-20 μg protein) was then mixed with 4x NuPage buffer
(Invitrogen) and run on a 4-12% Bis-Tris Gel (Invitrogen).
After SDS-PAGE (sodium dodecylsulfate polyacryl-
amide gel electrophoresis) the proteins were transferred
to nitrocellulose. Blocking was performed with 5% non-
fat dry milk overnight at 4°C. The primary antibody
(SERBP1, Eurogentec) was then incubated for 1 h at
room temperature at a dilution of 1:2000 for the cell
line-lysates and 1:1000 for the tissue-lysates. Western
blots were processed using a horseradish peroxidase goat
anti-rabbit IgG (1:2000; Dako). The Pierce ECL Western
Blotting Substrate was used for visualisation (Amersham
Biosciences, Amersham, UK).
The same membrane was then used for development
with a β-actin antibody (from mouse; Sigma) in a dilu-
tion of 1:2000. As secondary antibody a horseradish per-
oxidase goat anti- mouse IgG (1:2000; Dako) was used.
As positive controls, tissue-lysates of liver and placenta
were used. As a negative control rabbit IgG was used in
place of the SERBP1 antibody.
The intensity ratio of SERBP1 protein expression was
calculated densitometrically using a STORM-860 phos-
phoimager (Molecular Dynamics, Sunnyvale, CA, USA)
and normalised against the β-actin expression.
Statistical methods
For statistical evaluation the SPSS version 17.0 (SPSS
Inc, Chicago, IL) was used. Differences were considered
statistically significant when p-values were < 0.05. A
non-parametrically two-tailed Mann-Whitney U-test
was employed to analyse differences in expression levels.
A statistical association between clinicopathological and
molecular parameters was tested, using two-sided Fish-
er’s exact test. Recurrence-free (RFS) and overall survival
(OS) were calculated according to the Kaplan-Meier
equation.
For both TMAs, OS was defined as tumour-related
death and RFS as any local recurrence or distant recur-
rence whatever occurred first. Simple Cox proportional
hazard models were used with the biomarkers under in-
vestigation (nuclear and cytoplasmic IRS score of
SERBP1) to analyse the prognostic effect with the bio-
marker as an ordinal variable. Kaplan-Meier estimates
were used to display the survival curves and log rank
test was used to compare patients with high vs. low
SERBP1 expression. For multivariate analyses a Cox pro-
portional hazard model was constructed for OS and RFS
including tumour size (pT), nodal status (pN), Grading
(G), ER status, PgR status and HER2/neu status. After
Serce et al. BMC Cancer 2012, 12:597 Page 5 of 13
http://www.biomedcentral.com/1471-2407/12/597analysing both datasets independently a joint analysis of
the data was done for the adjusted hazard ratio with the
same covariates
Results
SERBP1 mRNA is abundantly expressed in human normal
breast tissue
SERBP1 is a molecule which is thought to regulate the
activity of the important breast cancer recurrence asso-
ciated protein PAI-1 [2,23-26]. Recently, overexpression
of SERBP1 was described in human ovarian cancer for
the first time [1]. Interestingly, uPA and PAI-1 are also
overexpressed in ovarian cancer and correlate with poor
clinical outcome [12,13]. To analyse the SERBP1 tran-
script level in human breast tissue we initiated our study
by investigating the distribution of SERBP1 mRNA ex-
pression in benign tissues derived from a variety of
human organs. Real time PCR analysis showed that
SERBP1 is abundantly expressed in human normal
breast tissue whereas relatively low levels could be
detected in the skeletal muscle, heart, spinal cord, brain
and thymus (Figure 1).
SERBP1 is not differentially expressed between normal
and malignant human breast tissue
We next analysed SERBP1 mRNA expression in
matched pairs of normal and malignant cryoconserved
human breast tissue (Figure 2) to decipher whether
SERBP1 gets deregulated during breast cancer develop-
ment as it has been shown in ovarian cancer [1]. In four
breast cancer samples the rate of SERBP1 mRNA was
slightly lower than in the corresponding normal tissues.
However SERBP1 expression was slightly higher in three
breast carcinomas compared with the matched normal
breast specimens. In summary, SERBP1 is not differen-
tially expressed between normal and malignant human
breast tissue and expression levels between theFigure 1 SERBP1 is abundantly expressed in human normal breast tis
performed on reverse transcribed RNA from benign tissues derived from d
skeletal muscle, heart, spinal cord, brain and thymus whereas comparativel
pancreas, cervix, salivary gland, testis and liver.respective groups were statistically not significant (P =
0.56) (Figure 2). Additionally, SERBP1 mRNA transcript
levels of the cancerous breast tissues did neither correl-
ate with the corresponding PAI-1 mRNA expression (P
= 0.21) nor with the PAI-1 protein levels (P = 0.29) deter-
mined by ELISA test (FEMTELLEW) (data not shown).
SERBP1 is expressed in breast epithelial cells and not in
the stroma analysed by non-radioisotopic in situ
hybridisation
SERBP1 expression was not differentially expressed be-
tween normal and cancerous breast tissue as analyzed
by realtime PCR analysis. To detect possible differential
expression at the cellular level, we applied non-
radioisotopic RNA in situ hybridisation in a subset
of normal (n = 10) and cancerous (invasive ductal type,
n = 10) breast tissue samples derived from the initial
evaluation TMA. SERBP1 mRNA was expressed in the
benign and malignant breast epithelial cells but not in
the stromal cells (Figure 3). However, also on the cellular
level, SERBP1 was not differentially expressed between nor-
mal and malignant breast tissue considering intensity and
regional heterogeneity of the SERBP1 signal (Figure 3).
SERBP1 antibody generation and validation by Western
blot analysis using breast cell lines
As we began our studies, commercial antibodies against
SERBP1 were not available for immunohistochemistry.
Therefore we generated a polyclonal SERBP1 antibody
which was applicable for immunohistochemistry. The
SERBP1 antibody was validated by Western blot ana-
lysis of benign (MCF12A, MCF10A) and malignant
(ZR75-1, BT20, HS578T, SKBR3, MDA-MB468 and
MDA-MB231) human mammary cell lines (Figure 4).
As expected from our RNA expression data, we could
detect a quite homogenous expression of SERBP1 pro-
tein in all cell lines. The calculated protein weight wassue. Semiquantitative realtime PCR analysis of SERBP1 expression was
ifferent human organs. SERBP1 mRNA expression was low in the
y high expression levels were detected in the mammary gland, spleen,
Figure 2 SERBP1 is not differentially expressed between normal and malignant human breast tissue in matched pairs. A collection of
cryoconserved matched pairs of normal (N; n = 7) and cancerous breast tissues (T; n = 7) was analysed for SERBP1 expression by semiquantitative
realtime PCR. SERBP1 RNA was upregulated in three tumour tissues compared to the corresponding normal breast tissues. In four cancerous
tissues SERBP1 expression was lower than in the corresponding normal breast tissue. Expression levels between the respective groups were
statistically not significant (P = 0.56).
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higher molecular weight of 50 kDa compared with the
deduced molecular weight of 44965 Da (www.expasy.
org/uniprot/Q8NC51#comments) was concordant with
previous published data regarding Western blotFigure 3 SERBP1 mRNA is expressed in breast epithelial cells but not
hybridisation SERBP1 expression was investigated by non-radioisotop
cancerous (n = 10) breast tissue samples derived from the initial TMA
expression in the epithelial cells (arrow) and no stromal (asterisk) staining u
sense RNA. (C, D) Invasive breast carcinoma (here: ductal type) also reveale
applying antisense SERBP1 RNA whereas no staining could be seen in strom
RNA. Magnifications: A, C: 40x; B, D: 200x.analysis [6] and may be the result of posttranslational
modification. The generated SERBP1 antibody was
further validated by a peptide competition experi-
ment using Western blot analysis (Additional file 1:
Figure S1).in stromal cells as shown by non-radioisotopic in situ
ic RNA in situ hybridisation in a subset of normal (n = 10) and
set. (A, B) Normal breast tissue with moderate SERBP1 mRNA
sing antisense SERBP1 RNA. (B) Insert shows no staining by SERBP1
d moderate SERBP1 mRNA expression in the epithelial cells (arrow)
al cells (asterisk) (D) Insert shows negative staining by SERBP1 sense
Figure 4 SERBP1 antibody validation by Western blot analysis
of breast cell lines. The SERBP1 antibody was validated by Western
blot analysis of benign (MCF12A, MCF10A) and malignant (ZR75-1,
BT20, HS578T, SKBR3, MDA-MB468 and MDA-MB231) human
mammary cell lines. Additionally, in line with the SERBP1 mRNA data,
SERBP1 protein expression in the normal mammary cell lines was
not significantly different from the SERBP1 protein expression in the
malignant mammary cell lines. β-actin displayed a homogenous
protein loading in the investigated cell lines.
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normal and cancerous human breast tissue analysing a
tissue microarray
Next we applied the validated SERBP1 antibody on tis-
sue microarrays. Two independent cohorts of breast
cancer specimens arranged on two different tissue
microarrays were analysed for SERBP1 expression by
immunohistochemistry. These represented an initial
evaluation set, consisting of 193 breast carcinomas and
48 normal breast tissues, and an independent validation
set, consisting of 605 breast carcinomas. In normal
breast tissue SERBP1 expression was heterogeneous with
low to abundant nuclear and cytoplasmic staining in the
epithelial cells whereas no staining could be seen in the
stroma (Figure 5A and B). In ductal carcinoma in situ
(Figure 5C and D) SERBP1 was expressed moderately in
the nucleus as well as in the cytoplasm. In invasive
breast carcinomas SERBP1 expression was generally very
differential with low (Figure 5E and F, ductal type) to in-
tense expression pattern in the nucleus as well as in the
cytoplasm of the mammary epithelial cells (Figure 5G
and H, ductal type). In whole, SERBP1 was expressed in
both the nucleus and the cytoplasm of benign and ma-
lignant mammary epithelial cells and not in the stroma
which is concordant with the results of the non-
radioisotopic in situ hybridisation. In addition, SERBP1
expression was heterogeneous in normal and breast can-
cer specimens. Differences between the respective
groups were statistically not significant which is in line
with the SERBP1 non-radioisotopic in situ hybridisation
data, the SERBP1 mRNA expression profile in tissues
as well as with the Western blot analysis of SERBP1 pro-
tein expression in cell lines. The median immunoreac-
tive scores (IRS) for nuclear (IRS = 6) and cytoplasmic
(IRS = 4) staining were each identical between normal
and cancerous breast tissues.Analysis of the initial evaluation TMA cohort
Data of the initial TMA cohort are presented in supple-
mentary tables and figures (Additional file 2: Table S1,
Additional file 3: Table S2, Additional file 1: Figure S1
and Additional file 4: Figure S2). In the initial TMA co-
hort, SERBP1 protein expression in breast carcinomas
(IRS >2) was not associated with tumour size, lymph
node status, histological grading, hormone receptor/
Her2 status, focality or histological type of tumour
(Additional file 2: Table S1). To investigate a possible
impact of SERBP1 expression on patients’ clinical out-
come we calculated univariate survival probability for
nuclear and cytoplasmic SERBP1 IRS scores with respect
to immunohistochemical results. We found that a higher
SERBP1 expression (nuclear and cytoplasmic IRS score
as ordinal variable) was nominally associated with a
favourable prognosis for both, the nuclear staining and
the cytoplasmic staining, regarding OS and RFS
(p-values between 0.058 and 0.204), however none of the
analyses reached statistical significance. The best cut-off
in this cohort was a nuclear score greater than 2. The
Kaplan-Meier analysis (P = 0.301) is shown in Additional
file 3: Table S2 and Additional file 4: Figure S2. Patients
who showed abundant SERBP1 expression in the
tumour had an estimated mean RFS of 84 months
(95% confidence interval: 74-94) compared to 67 months
(95% confidence interval: 53-81) in patients with nega-
tive/weak SERBP1 expression. Although overall survival
was also not significantly associated with abundant
SERBP1 expression, there was a trend towards
favourable prognosis regarding patients with strong
SERBP1 expression (Additional file 3: Table S2).
Validation in the Bavarian Breast Cancer Cases and
Controls (BBCC) TMA cohort
To validate our results of the initial evaluation set of
tumours, we further analysed a second larger cohort
(BBCC) of breast cancer specimens on a TMA. In this
validation cohort the IRS score was available for 605 in-
vasive breast cancer cases. The mean patients’ age was
56 years (± 12). Chemotherapy was given to 48% of all
patients and 92% of all hormone receptor positive
patients received an antihormonal therapy. The median
nuclear IRS score was 3 with 15% (n = 91) of tumours
having a low score of 0 to 2 and 85% (n = 514) showing
abundant expression of SERBP1 (IRS > 2). The cytoplas-
mic staining showed very similar results with a median
score of 4 and 18% of the tumors having a core of 0 to 2
and 82% of the tumors having an abundant SERBP1
expression.
In this larger cohort we found a significant correlation
(P = 0.008) between nuclear SERBP1 expression and
favourable prognosis in recurrence-free survival analysis
Figure 5 SERBP1 protein is not differentially expressed between normal and cancerous human breast tissue on TMA. SERBP1 protein
was expressed heterogeneously in the nucleus as well as in the cytoplasm of normal and cancerous breast epithelial cells whereas no staining
could be detected in stromal cells. Differences between the respective groups were statistically not significant. (A, B) Normal breast tissue
showed moderate nuclear and cytoplasmic SERBP1 protein expression (IRS = 6) in the epithelial cells. (C, D) Ductal carcinoma in situ revealed a
moderate nuclear and cytoplasmic SERBP1 staining (IRS = 6). (E, F) In invasive breast carcinoma (here: ductal type) SERBP1 expression was low
(example shows nuclear and cytoplasmic staining with an IRS = 1). (G, H) Invasive breast carcinoma (here: ductal type) also displayed abundant
nuclear (IRS = 8) and cytoplasmic SERBP1 protein expression (IRS = 12). Magnifications: A, C, E, G: 40x; B, D, F, H: 400x.
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http://www.biomedcentral.com/1471-2407/12/597(Figure 6). Although overall survival was not significantly
associated with nuclear SERBP1 expression, we could see
a trend towards favourable prognosis (P = 0.09) (Figure 7).
In multivariate analysis, SERBP1 immunohistochemical
expression turned out to be an independent predictor for
RFS (HR = 0.59; 95% CI: 0.35 to 0.98, P = 0.039), but not
for OS (HR = 0.79; 95% CI: 0.43 to 1.45) (Table 1). The
cytoplasmic score showed no association with survival
outcome (data not shown).
Both datasets were analysed together to calculate the
Cox proportional hazard ratios, adjusted for pT, pN,
grading, ER/PR status, and HER2/neu status. The hazard
ratio for recurrence-free survival gained in significance
level with a HR = 0.64 (95%CI: 0.44 to 0.94; P = 0.02).
The hazard ratio for overall survival remained not sig-
nificant for SERBP1 with a HR of 0.92 (95%CI: 0.58 to
1.46; P = 0.73). Again the cytoplasmic score showed no
association with survival outcome (data not shown).
Abundant SERBP1 expression is associated with low PAI-1
protein level in Western blot analysis
Surprisingly, in the survival analyses abundant SERBP1
expression was associated with favourable prognosis
which is inverse to the prognostic impact of the PAI-1
protein level because high PAI-1 protein levels are
known to indicate unfavourable prognosis in human
breast cancer [10,11]. Consequently we hypothesised
that abundant SERBP1 protein expression might be
related to low PAI-1 protein levels. Therefore we next
determined SERBP1 protein expression in extracts of
cryoconserved human breast cancer tissues with lowFigure 6 Recurrence-free survival displayed as Kaplan Meier curves fr
expression showed favourable prognosis in recurrence-free survival analysis(n = 8) and high (n = 8) levels of the protein PAI-1 as
determined by the FEMTELLEW ELISA test. As we
expected, extracts with low PAI-1 protein levels were
associated with intense SERBP1 expression by trend.
Vice versa high PAI-1 protein levels correlated with low
SERBP1 expression although differences between the re-
spective groups were statistically not significant (P =
0.281) (Figure 8). The mean densitometric intensity of
SERBP1 expression in extracts with low PAI-1 protein
levels was 1.31 arbitrary units (standard deviation (SD)
± 1.26) and 0.587 (SD ± 0.53) arbitrary units in extracts
with high PAI-1 protein levels.
Discussion
SERBP1 is a PAI-1 mRNA binding protein that putatively
regulates PAI-1 abundance by stabilising or destabilising
PAI-1 mRNA [2]. Indeed, in rat hepatoma cells it could
be shown that binding of SERBP1 protein to the PAI-1
mRNA leads to degradation and destabilisation of PAI-1
mRNA [3]. However, this interaction has not been ana-
lysed in human tissue including normal and cancerous
breast tissue. In breast cancer, PAI-1 is associated with
tumour invasion and metastasis, thus high uPA/PAI-1
protein levels are indicators of poor prognosis in this
tumour entity [10,11]. Overexpression of PAI-1 has been
reported in several human solid tumours besides breast
cancer, including colorectal, gastric and cervical cancer
[11,28-30]. Until now, SERBP1 overexpression was just
shown in human ovarian carcinomas and was associated
with advanced tumour stage [1]. In the current study, a
systematic characterisation of SERBP1 expression inom the BBCC TMA. Breast cancer patients with abundant SERBP1
(P = 0.008).
Figure 7 Overall survival displayed as Kaplan Meier curves from the BBCC TMA. Breast cancer patients overexpressing SERBP1 also
exhibited favourable prognosis by trend in overall survival (P = 0.09).
Serce et al. BMC Cancer 2012, 12:597 Page 10 of 13
http://www.biomedcentral.com/1471-2407/12/597human breast cancer is presented for the first time at
both the mRNA and the protein level, including a large
cohort of breast carcinoma specimens that has been
investigated by correlative analysis using clinicopatholo-
gical parameters and patients’ survival data. We foundTable 1 Multivariate analysis (BBCC validation TMA) of recurr
HER2 and SERBP1
Characteristic N Adjusted Hazard R




pNa 0 351 1
1 254 2.41
Grading 1 49 1
2 361 1.40
3 195 1.95
ER Neg 143 1
Pos 462 1.19
PR Neg 205 1
pos 400 0.58
HER2 Neg 511 1
pos 94 1.06
SERBP1 IRS 0-2 91 1
IRS 3-12 514 0.59
aAccording to Sobin LH, Wittekind CH: UICC: TNM Classification of Malignant Tumou
pT: Pathological assessment of the primary tumour.
pN: Pathological assessment of the regional lymph nodes.
CI: Confidence interval.that SERBP1 is not differentially expressed between nor-
mal and cancerous breast tissue as well as between be-
nign and malignant breast epithelial cell lines.
Differences in expression levels between the respective
groups were statistically not significant which wereence-free survival, adjusted for pT, pN, Grading, ER, PR,
atio 95% CI p-value
1.10 to 3.10 0.02
1.64 to 7.37 0.001
3.81 to 13.80 1.7E-09
1.47 to 3.94 0.0005
0.43 to 4.57 0.57
0.57 to 6.64 0.29
0.63 to 2.24 0.59
0.33 to 1.04 0.067
0.60 to 1.85 0.85
0.35 to 0.98 0.039
rs. 6th edition, New York: Wiley; 2002 [27].
Figure 8 Abundant SERBP1 expression is associated with low PAI-1 protein level in Western blot analysis. SERBP1 protein expression was
investigated in extracts of cryoconserved human breast cancer tissues with low (n = 8) and high (n = 8) levels of protein PAI-1 by using Western
blot analysis. Extracts with low PAI-1 protein levels (number: 1-3) were associated with intense SERBP1 expression by trend and vice versa high
PAI-1 protein levels (number: 4-6) correlated with low SERBP1 expression. Differences between the respective groups were statistically not
significant (P = 0.281). β-actin showed a relatively homogenous protein loading in the investigated lysates.
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malignant mammary cell lines. These results were fur-
ther encouraged by applying non-radioisotopic RNA in
situ hybridisation on a subset of normal and cancerous
breast tissues. Moreover, the lack of differential SERBP1
protein expression between benign and malignant breast
samples could be confirmed by immunohistochemistry
on a tissue microarray. Using this technique, SERBP1
protein expression was correlated with patients’ survival
data. Interestingly, in our initial cohort of breast carcin-
omas (n = 193) we found a trend between abundant
SERBP1 expression and favourable prognosis in
recurrence-free survival (RFS; P = 0.301) pointing to-
wards a potential protective role of SERBP1 in breast
cancer development. Analysis of the second, independ-
ent breast cancer cohort (n = 605) confirmed this notion.
In this validation TMA set, nuclear SERBP1 expression
(IRS >2) was significantly correlated with favourable
prognosis in recurrence-free survival analysis (P = 0.008)
and turned out to be an independent prognostic marker
in multivariate analysis. In overall survival analysis, nu-
clear SERBP1 expression was also associated with
favourable prognosis (P = 0.09), but did not reach statis-
tical significance. In summary, our survival analyses
showed a correlation between nuclear SERBP1 expressionand favourable prognosis which is inverse to the prognos-
tic impact of PAI-1 as high PAI-1 protein levels are
related to unfavourable prognosis in human breast cancer
[10. 11]. An explanatory model for this inverse relation-
ship between SERBP1 and PAI-1 could be the finding in
rat hepatoma cells where high SERBP1 protein levels lead
to degradation of PAI-1 mRNA and consecutively to low
PAI-1 protein levels [3]. This explanation is encouraged
by our Western blot analysis where breast carcinoma
extracts with high PAI-1 protein levels showed weak
SERBP1 protein expression by trend and vice versa breast
carcinoma extracts with low PAI-1 protein levels showed
abundant SERBP1 protein expression. However, this po-
tential relationship between PAI-1 and SERBP1 protein
levels has to be further validated in independent studies.
Interestingly, we did not find a significant correlation be-
tween nuclear SERBP1 expression and nuclear progester-
one receptor status in both TMAs as SERBP1 is known to
mediate the membranous progesterone effect by binding
to PGRMC1 [6]. The role of SERBP1 regarding the inter-
action with the nuclear progesterone receptor is unclear
to date [31]. Progesterone receptors are classically defined
as ligand-activated transcription factors, but also function
at or near the plasma membrane to directly activate pro-
tein kinase pathways (namely, c-Src and the MAP kinase
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is commonly called “rapid signalling”. The function of
rapid signalling is unknown, but may provide positive
regulation of PR-containing transcriptional complexes by
direct phosphorylaton of PR or coregulatory molecules
[25]. The relation between SERBP1 and progesterone re-
ceptor is quite important because progesterone receptors
play a major role in the regulation of growth, survival and
differentiation of normal and malignant breast epithelial
cells [32,33]. Activated progesterone receptors are with-
held in the nucleus and associate with numerous coregu-
latory molecules, including histone acetyl transferases,
chromatin remodelling machines and TRAP/DRIP com-
plexes that recruit RNA polymerase II [32]. Moreover, a
positive progesterone receptor status is usually correlated
with a positive oestrogen receptor status and favourable
prognosis in human breast cancer [32,33]. However, the
role of progesterone in the development of human breast
cancer is poorly understood and controversially discussed
[32,33]. Therefore inhibition of the progesterone receptor
has not been established in the treatment of human
breast cancer so far [32,33].
In summary, SERBP1 is a potential prognostic marker
in human breast carcinoma. In further studies we are
going to analyse the exact function of SERBP1 in the de-
velopment of breast cancer and its interaction with the
progesterone receptor and PAI-1 in this context.
Conclusions
In conclusion, our analyses showed no differential
SERBP1 expression between normal and cancerous
human breast tissue both at the RNA and protein level.
Surprisingly, nuclear SERBP1 expression in breast car-
cinoma was significantly associated with favourable
prognosis in recurrence-free survival analysis which is
inverse to the prognostic impact of the proteins uPA/
PAI-1. An explanation for this inverse relationship might
be the degradation of PAI-1 mRNA by binding of the
SERBP1 protein to it as it was described in rat hepatoma
cells previously and which was underlined by our West-
ern blot analyses by trend. Furthermore, SERBP1 may
represent a novel breast tumour marker with prognostic
significance. However, the putative function of SERBP1
in breast carcinogenesis and its relation to PAI-1 has to
be further analysed in prospective studies.
Additional files
Additional file 1: Figure S1. Validation of SERBP1 antibody in Western
blot analysis/Competition test. The SERBP1 antibody was validated in
Western blot analysis by using the peptide competition test. SERBP1
protein expression was investigated in extracts of cryoconserved
placenta, liver and in the breast cancer cell lines MDA-MB 231 and BT20.
After peptide competition the SERBP1 protein signal was absent or weak
whereas β-actin displayed a homogenous protein loading.Additional file 2: Table S1. Clinicopathological and
immunohistochemical parameters in relation to SERBP1 immunoreactivity
in the evaluation TMA.
Additional file 3: Table S2. Univariate analysis of factors regarding
overall survival (OS) and recurrence-free survival (RFS) in the evaluation
TMA.
Additional file 4: Figure S2. Correlation of SERBP1 expression and
patient prognosis according to univariate Kaplan-Meier analysis. Breast
cancer patients overexpressing SERBP1 presented favourable prognosis in
recurrence-free survival analysis by trend (P = 0.301).
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